AdvaMed Statement on Passage of Continuing Resolution
WASHINGTON, D.C. - The Advanced Medical Technology Association (AdvaMed) issued the following statement from President and CEO Scott Whitaker on the passage of the current continuing resolution, which includes a two-year suspension of the medical device excise tax:
"AdvaMed applauds passage of the two-year suspension of the medical device tax. This suspension is good news for American patients and American innovation. Congress' action - just days before medical technology innovators were set to start cutting checks to the IRS - means funds will not be diverted from current investments in jobs, capital improvements and research into new treatments & cures.
"We appreciate Congress' action and the leadership of so many Members who have worked to keep this crucial issue front and center.
"While the two-year suspension is welcome, it is only an interim step toward the truly needed action by Congress to fully repeal this tax and unleash the promise of medtech innovation. We look forward to continuing to work with the Hill on a bipartisan basis to drive towards permanent relief."
Members of the BioFlorida network include emerging and established life science companies, universities, research institutions, hospitals, medical centers, incubators, economic development agencies, investors and service providers.